
more
April 10, 2008
Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA --
more
April 2, 2008
Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis --
more
March 31, 2008
ExonHit Appoints a New Management Board --
more
March 27, 2008
Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update --
more
March 25, 2008
Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug --
more
March 10, 2008
BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing --
more
February 29, 2008
February 29, 2008: Santhera Reports Financial Results and Significant Operational Progress for 2007 --
more
February 7, 2008
Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer --
more
February 6, 2008
Astex Receives IND Approval for its Small Molecule HSP90 Inhibitor AT13387; Astex Announces Extension of Drug Discovery Alliance --
more
February 6, 2008
Apex Bioventures and Dynogen Pharmaceuticals Announce Definitive Merger Agreement --
more
February 4, 2008
Mitralign Successfully Completes First Human Case --
more
January 31, 2008
AVEO Initiates Phase 1b Combination Clinical Trial of Novel Triple VEGF Receptor Inhibitor AV-951 in Metastatic Renal Cell Carcinoma --
more
January 30, 2008
Radius Announces Launch of RAD1901 Clinical Program for the Treatment of Hot Flashes —CTA Acceptance in the Netherlands Triggers Milestone Payment to Eisai --
more
January 22, 2008
Xanthus Announces Oral Fludarabine NDA Accepted for Review by U.S. FDA --
more
January 3, 2008
AVEO Pharmaceuticals Appoints Kenneth M. Bate to Board of Directors --
more
December 14, 2007
ACADIA Pharmaceuticals Announces Completion of Enrollment of ACP-104 Phase IIb Clinical Trial Ahead of Schedule --
more
December 10, 2007
Critical Therapeutics Receives $5.0 Million Milestone Payment from DEY for Commercial Launch of ZYFLO CR --
more
December 4, 2007
AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project --
more
December 4, 2007
Coherex Medical Hires Top Medical Industry Veteran to Fill Global Market Development Seat --
more
December 3, 2007
Mitralign Announces Closing of Series C Financing --
more
November 29, 2007
Health Canada Accepts Santhera's Submission for Marketing Authorization of SNT-MC17 in Friedreich's Ataxia --
more
November 14, 2007
Dicerna, Startup Based on RNAi Biology, Licenses IP from City of Hope and Closes $13 Million Series A Financing --
more
November 12, 2007
Santhera Showcases Potential and Progress of its Clinical Development Pipeline --
more
November 9, 2007
Santhera Starts Phase IIb Clinical Trial with JP-1730 in Dyskinesia in Parkinson's Disease --
December 29, 2006
Merck & Co., Inc. Announces Completion of Acquisition of Sirna Therapeutics, Inc. --
more
October 18, 2006
Trubion Pharmaceuticals Announces Initial Public Offering --
more
more
November 8, 2007
ExonHit Completes a Prototype to Detect Alzheimer’s Disease from Blood --
more
November 6, 2007
Results from Phase 1 Study of AVEO’s Novel Triple VEGF Receptor Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved Partial Response or Stable Disease --
more
November 2, 2007
Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease --
more
November 1, 2007
AVEO Pharmaceuticals Appoints David Johnston as Chief Financial Officer --
more
November 1, 2007
Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies --
more
October 29, 2007
Santhera Reports Encouraging, First Data from Phase IIa Clinical Trial with SNT-MC17 in Duchenne Muscular Dystrophy --
more
October 25, 2007
Elixir Pharmaceuticals Names Paul M. Martha, M.D. as Chief Medical Officer --
more
October 24, 2007
Santhera's CSO Thomas Meier Receives BioValley Award for Scientific and Entrepreneurial Merits --
more
October 15, 2007
Dynogen's Oral Prokinetic Drug, DDP733, Shown to Reduce Reflux in Phase 1B Study --
more
October 15, 2007
Critical Therapeutics Announces Enrollment in Phase III Trial of Zileuton in Patients with Acute Exacerbations of COPD --
more
October 10, 2007
Critical Therapeutics Announces the Issuance of Four New Patents for Its Alpha-7 and HMGB1 Preclincial Programs --
more
October 8, 2007
Xanthus Initiates Pivotal Phase 3 Trial of Xanafide in Secondary Acute Myeloid Leukemia --
more
October 8, 2007
Critical Therapeutics and Dey, L.P. Launch Perforomist(TM) (Formoterol Fumarate) Inhalation Solution --
more
October 4, 2007
Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia --
more
October 3, 2007
Coherex Medical, Inc., a privately held medical device company,today announced it has successfully completed the first human cases of its Coherex FlatStent(TM) PFO Closure System --
more
October 2, 2007
AVEO Pharmaceuticals to Utilize Peptech’s Breakthrough Technology to “Humanise” Internal Drug Candidates --
more
October 2, 2007
OSI Pharmaceuticals and AVEO Pharmaceuticals Enter into an Oncology Drug Discovery and Translational Research Collaboration --
more
October 1, 2007
Critical Therapeutics Initiates Phase I Clinical Trial of the R(+) Isomer of Zileuton --
more
September 28, 2007
Santhera Announces Start of US Phase III Clinical Trial with SNT-MC17 in Friedreich's Ataxia and Provides Details on Study Design --
more
September 27, 2007
Ceres Raises $75 Million in Late-Stage Financing --
more
September 27, 2007
BrainCells Inc., Taisho Pharmaceutical Co., Ltd. Sign Licensing Agreement for Novel CNS Program --
more
September 27, 2007
Critical Therapeutics and Dey Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets --
more
September 25, 2007
Critical Therapeutics Highlights Near-Term Milestones to Drive Commercial Success and Clinical Development --
more
September 24, 2007
Elixir Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering --
more
September 21, 2007
Santhera to Seek Canadian Market Approval for SNT-MC17 in Friedreich's Ataxia --
more
September 17, 2007
Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis --
more
September 13, 2007
Xanthus' Xanafide is Unaffected by Multi-Drug Resistance in In Vitro Preclinical Studies in Leukemia Cells --
more
September 13, 2007
Critical Therapeutics Announces Publication of Results from Two Asthma Studies --
more
September 10, 2007
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis --
more
September 7, 2007
Publication in LANCET Neurology Highlights Potential of Santhera's SNT-MC17 for Friedreich's Ataxia --
more
August 29, 2007
Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908 --
more
August 29, 2007
FlowMedica Announces Completion of the Benephit System Renal Infusion Therapy (Be-RITe) Registry --
more
August 28, 2007
Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials --
more
August 17, 2007
Concentric Medical, Inc. Files Registration Statement for Proposed Initial Public Offering --
more
August 17, 2007
Santhera's 2007 Interim Results Reflect Increased Investment in Advanced Development Pipeline --
more
August 16, 2007
European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera --
more
August 6, 2007
BioProcessors Raises $10 Million --
more
August 2, 2007
Santhera and Takeda Extend European Marketing Collaboration for SNT-MC17 into Duchenne Muscular Dystrophy --
more
July 26, 2007
Elixir Pharmaceuticals to Present Data from Programs to Treat and Prevent Metabolic Diseases --
more
July 16, 2007
Intechra Adds National Logistics Network, Two Acquisitions --
more
July 12, 2007
Memory Pharmaceuticals Completes Enrollment in Phase 2a MEM 3454 Alzheimer's Disease Trial --
more
July 10, 2007
Critical Therapeutics Initiates Phase IV Study Evaluating ZYFLO CR(TM) in Asthma Patients on Inhaled Corticosteroids Whose Symptoms Are Poorly Controlled --
more
July 2, 2007
Santhera Licenses Omigapil for Treatment of Rare Neuromuscular Diseases --
more
June 26, 2007
Critical Therapeutics' Zileuton Provides Additional Asthma Control When Combined with Inhaled Corticosteroids --
more
June 26, 2007
ACADIA Pharmaceuticals Initiates Phase IIb Clinical Trial with ACP-104 in Patients with Schizophrenia --
more
June 25, 2007
Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting --
more
June 25, 2007
Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast(R) to Maintain Glycemic Control in Patients with Type 2 Diabetes --
more
June 19, 2007
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia --
more
June 18, 2007
AVEO Pharmaceuticals' CEO Tuan Ha-Ngoc Receives Ernst & Young New England Entrepreneur of the Year® Award --
more
June 12, 2007
Xanthus Completes Special Protocol Assessment with FDA for Phase 3 Registration Trial of Xanafide in Patients with Secondary Acute Myeloid Leukemia --
more
June 12, 2007
Critical Therapeutics Announces the Publication of Data for ZYFLO CR(TM) (Zileuton) Extended-Release Tablets in the Journal of Asthma --
more
June 11, 2007
ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis --
more
June 7, 2007
Agilent Technologies Adds Strength to Its Life Science Business with Acquisition of Stratagene --
more
June 7, 2007
Dynogen Reports Positive Results in Phase 1B GERD Study --
more
June 4, 2007
Cardiome and Astellas Announce Positive Results from ACT 2 Trial --
more
June 3, 2007
Xanthus Announces Phase 1 Results for P2045 - a Targeted Agent for Non-Small Cell Lung Cancer --
more
June 2, 2007
Xanthus Presents Phase 2 Data Showing Xanafide is Associated with Complete Remissions in Secondary AML --
more
May 31, 2007
FDA Approves Critical Therapeutics' Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for Asthma --
more
May 22, 2007
Intechra Secures Additional $30 Million in Equity Capital --
more
May 15, 2007
Solstice Neurosciences, Inc. Announces Commercialization Agreement --
more
May 14, 2007
Critical Therapeutics' Sales Force Gains Access to a Second Product as FDA Approves Co-Promotion Partner's New Treatment for COPD --
more
May 3, 2007
Xanthus Presents Novel Approach for Autoimmune Disease Reversal with Symadex --
more
May 3, 2007
AVEO Pharmaceuticals Closes $53 Million in Series D Funding --
more
May 2, 2007
Critical Therapeutics' Co-Promotion Partner, DEY, L.P., Launches U.S. Sales and Marketing of ZYFLO(R) for Asthma --
more
April 23, 2007
CircuLite Closes an Additional $5M in Series B Private Placement Funding --
more
April 11, 2007
Xanthus Acquires from Johns Hopkins University Exclusive License to Patent Estate Covering FLT3 Pathway as a Target for Treating Autoimmune Diseases --
more
April 6, 2007
Stratagene Signs Definitive Agreement to Be Acquired by Agilent Technologies --
more
April 5, 2007
Memory Pharmaceuticals Completes Enrollment in Phase 2a MEM 1003 Alzheimer's Disease Trial --
more
April 4, 2007
AVEO enters into Worldwide License and Development Agreement with Schering-Plough for AV-299, AVEO's Novel Anti-HGF Antibody --
more
April 4, 2007
ACADIA Pharmaceuticals Announces Pricing of Public Stock Offering --
more
April 2, 2007
Radius Raises $57.5 Million in Second Private Financing Round --
more
April 2, 2007
Nfocus Neuromedical Inc. Raises over $20 Million in Series B Financing --
more
March 28, 2007
Santhera Announces Appointment of Cesare Mondadori as Head of Research --
more
March 27, 2007
BrainCells and Lundbeck Form CNS Drug Research Collaboration --
more
March 22, 2007
Xanthus Initiates a Phase 1 Study of Clomet for Treatment of Solid Tumors --
more
March 20, 2007
Radius Begins Phase II Clinical Trial of BA058 for Osteoporosis --
more
March 19, 2007
ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial --
more
March 15, 2007
ExonHit Identifies a Panel of Genes to Diagnose, From Blood, Alzheimer's Disease --
more
March 14, 2007
Tragara Pharmaceuticals, Inc. Announces Corporate Launch and Series A Financing --
more
March 14, 2007
Critical Therapeutics and DEY, L.P. Enter into Co-Promotion Agreement for Respiratory Care Products --
more
March 13, 2007
Memory Pharmaceuticals Commences Phase 2a Trial of MEM 3454 in Alzheimer's Disease --
more
March 6, 2007
Avalon Pharmaceuticals and Merck & Co., Inc. Establish a Drug Discovery, Development and Commercialization Collaboration --
more
March 5, 2007
Lilly Announces Acquisition of Hypnion --
more
March 5, 2007
FlowMedica: Targeted Renal Therapy for Patients at Risk for Contrast-Induced Nephropathy --
more
March 5, 2007
Asterand Offers Researchers Internet Access to RNA to Speed Drug Discovery --
more
March 2, 2007
Santhera Reports Successful 2006 --
more
March 1, 2007
Santhera Board Proposes the Election of Klaus Schollmeier to the Company's Board --
more
February 20, 2007
Cyberkinetics Files to Market Andara(TM) OFS(TM) Therapy for Acute Spinal Cord Injury under Humanitarian Device Exemption --
more
February 13, 2007
Critical Therapeutics Announces Beckman Coulter Exercises Option to Continue HMGB1 Diagnostic Development --
more
February 13, 2007
Elixir Pharmaceuticals and Siena Biotech S.p.A. Enter Agreement to Evaluate SIRT1 Inhibitors in Huntington's Disease --
more
February 13, 2007
Dynogen Reports Positive Results in Phase 2 IBS-c Study --
more
January 31, 2007
Santhera Intends Early Filing in Europe for SNT-MC17/idebenone in Friedreich's Ataxia --
more
January 31, 2007
Santhera Updates Development Strategy for SNT-MC17/idebenone in Friedreich's Ataxia in the US --
more
January 30, 2007
Critical Therapeutics Licenses Rights for Vagus Nerve Stimulation Device to Innovative Metabolics --
more
January 19, 2007
Claros Diagnostics Secures $7.8 Million Series A Financing to Develop Handheld Point-of-care Diagnostics Platform --
more
January 17, 2007
Elixir Pharmaceuticals Presents New Data Highlighting Ghrelin Inhibition as a Potential Method for Regulating Metabolism and Treating Diabetes --
more
January 16, 2007
Trubion Announces Completion of Enrollment and Dosing of Patients in Phase IIb Clinical Trial of TRU-015 for the Treatment of Rheumatoid Arthritis --
more
January 8, 2007
Solexa Genome Analysis System Achieves 1G Performance Milestone --
more
January 4, 2007
AVEO acquires Clinical Stage Anti-Cancer Compound from Kirin --
more
December 15, 2006
Cohesive Technologies Inc.: Thermo Fisher Scientific Acquires Provider of Sample Extraction and Liquid Chromatography --
more
December 15, 2006
Critical Therapeutics Announces NIH-Sponsored Study to Investigate the Efficacy Of ZYFLO(R) In Patients with Acute Exacerbations Of COPD --
more
December 12, 2006
Abbott and Enanta Form Worldwide Alliance to Develop and Commercialize HCV Protease Inhibitors --
more
December 11, 2006
Xanthus Presents Preclinical Data Demonstrating Potent Symadex Activity in Leukemia Cells --
more
December 11, 2006
Memory Pharmaceuticals Announces Release of Clinical Hold on MEM 3454 --
more
December 4, 2006
Xanthus Completes Enrollment of Phase 2 Trial of Xanafide for the Treatment of Secondary AML --
more
December 4, 2006
Astex Therapeutics Appoints John Aston Chief Financial Officer --
more
November 30, 2006
Xanthus Secures $25 Million to Advance Development of Its Pipeline --
more
November 30, 2006
Santhera and Biozentrum Basel participate in the pan-European TREAT-NMD initiative to advance the treatment of rare neuro-muscular diseases --
more
November 29, 2006
ImpactRx, Inc. Names Altus President and Chief Executive Officer --
more
November 27, 2006
Memory Pharmaceuticals Completes Enrollment for MEM 1003 Bipolar Trial --
more
November 20, 2006
Memory Pharmaceuticals Earns Milestone Payment for Phase 2a Trial of MEM 1003 in Bipolar Disorder --
more
November 15, 2006
The Leukemia & Lymphoma Society and Ensemble Discovery Corp. Initiate Research Program to Apply New Technology to Better Diagnose Blood Cancers --
more
November 13, 2006
NIH and Santhera Announce Positive Results of Study with SNT-MC17/idebenone in Friedreich's Ataxia --
more
November 8, 2006
Solstice Neurosciences Raises $85 Million in Private Financing --
more
November 7, 2006
Mitralign Shines at TCT 2006; Performs Live Case & Reveals Clinical Strategy --
more
November 1, 2006
Pathway Medical Closes $25 Million in Funding --
more
November 1, 2006
Critical Therapeutics Announces Closing of $20.0 Million Registered Direct Offering --
more
October 31, 2006
Memory Pharmaceuticals to Receive $2 Million Milestone from Roche Related to MEM 3454 --
more
October 30, 2006
Merck & Co., Inc. to Acquire Sirna Therapeutics, Inc. --
more
October 27, 2006
Critical Therapeutics Outlines New Business Strategy Focusing on Controlled-Release and Intravenous Formulations of Zileuton --
more
October 27, 2006
Critical Therapeutics to Sell 7.5 Million Shares of Registered Common Stock and Warrants to Purchase 3.7 Million Shares of Common Stock --
more
October 25, 2006
VaxInnate Secures $40 Million Series C Financing --
more
October 24, 2006
Asterand Isolates New Approach to Arthritis Research --
more
October 24, 2006
Alantos Pharmaceuticals and Servier Form Collaboration --
more
October 23, 2006
AVEO Pharmaceuticals Initiates Clinical Development of AV-412 in Cancer Patients with Advanced Solid Tumors --
more
October 23, 2006
VaxInnate Reports Promising Results for Novel Influenza Vaccine Candidates --
more
October 23, 2006
BrainCells and Organon to Collaborate in Discovery and Development of CNS Drugs --
more
October 19, 2006
ExonHit to Identify a Blood Diagnostic for Atherosclerosis --
more
October 18, 2006
Cyberkinetics Enters into Definitive Agreements for $10.0 Million Private Placement --
more
October 18, 2006
Solexa Announces Sequencing of a Human X-Chromosome --
more
October 17, 2006
Critical Therapeutics Announces Acceptance of Controlled-Release Zileuton New Drug Application for Review by FDA --
more
October 3, 2006
Xanthus Pharmaceuticals Expands Oncology Pipeline with Late-Stage Oral Fludarabine from Schering AG --
more
October 2, 2006
Biopharmaceutical Firm Trubion Plans 4 Million IPO Shares --
more
October 2, 2006
Technology behind Sirna Therapeutics subject of the 2006 Nobel Prize for Physiology and Medicine --
more
September 28, 2006
Memory Pharmaceuticals Achieves Milestone in PDE10 Collaboration With Amgen --
more
September 28, 2006
Xanthus' Symadex Can Reverse Disease in Preclinical Multiple Sclerosis Animal Model --
more
September 28, 2006
AVEO and XOMA Enter Into Supply Agreement for AVEO’s Novel Anti-HGF Antibody --
more
September 25, 2006
ACADIA Pharmaceuticals Announces Accelerated Timing of ACP-103 Phase II Trial in Patients with Schizophrenia --
more
September 22, 2006
Santhera Appoints MJ Roach as Vice President Marketing and Sales --
more
September 19, 2006
Kurt H. Kruger Joins Cyberkinetics as Chief Financial Officer --
more
September 19, 2006
ExonHit Therapeutics Extends Strategic Alliance with Allergan --
more
September 15, 2006
Santhera Appoints New Board Directors --
more
September 14, 2006
Xanthus Presents In Vitro Data Demonstrating that Symadex Is a Potent and Selective Inhibitor of FLT3 --
more
September 13, 2006
Dynogen Initiates Phase 1b Trial of DDP733 in Gastroesophageal Reflux Disease (GERD) — New Approach for Treating Nighttime Heartburn --
more
September 12, 2006
Radius & Karo Bio Announce Licensing Agreement for Novel SARM Compounds --
more
September 6, 2006
FDA Grants Humanitarian Use Device Designation to Cyberkinetics' Andara(TM) OFS Device for Acute Spinal Cord Injuries; Designation Marks Critical Regulatory Step Toward Commercialization --
more
September 6, 2006
Xanthus Pharmaceuticals Licenses Novel Cancer Targeting Agents From Schering AG, Berlin --
more
September 5, 2006
Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 1003 in Bipolar Disorder --
more
September 5, 2006
Santhera and Juvantia to Collaborate on Development of Phase II Product for Dyskinesia in Parkinson's Disease --
more
August 31, 2006
Exelixis Files IND Application for XL228 --
more
August 31, 2006
Solexa Appoints Blaine Bowman and Roy Whitfield to Board of Directors --
more
August 23, 2006
Critical Therapeutics Announces Results of Phase I/II Trial of Intravenous Formulation of Zileuton --
more
August 10, 2006
Sirna Therapeutics Reports Final Results from Phase 1 Study on Its RNAi-Based Therapeutic for Age-Related Macular Degeneration --
more
August 10, 2006
BrainCells In-Licenses Clinical-Stage CNS Compound From Mitsubishi Pharma --
more
August 7, 2006
Radius Licenses Worldwide Exclusive Rights to Estrogen Receptor-Beta Agonists --
more
August 3, 2006
Solexa Appoints Joseph Whitters to Board of Directors --
more
July 31, 2006
Critical Therapeutics Submits New Drug Application for Controlled-Release Formulation of Zileuton To FDA --
more
July 17, 2006
Memory Pharmaceuticals Achieves Milestone Under Nicotinic Alpha-7 Collaboration With Roche --
more
July 13, 2006
Cyberkinetics' Neural Sensing Technology Highlighted in Second Study Published in Nature --
more
July 12, 2006
MicroMed Announces Hiring of Alan Totah as Senior Vice President of Regulatory Affairs and Quality Systems --
more
July 11, 2006
Solexa Announces Initial System Shipments; Early Access Program Underway with Leading Genome Institutes --
more
July 10, 2006
Ceres Announces Genomics Milestone in Energy Crop Enhancement Program --
more
July 10, 2006
PowderMed to Conduct Clinical Trial of its Novel DNA-Based H5N1 (Avian) Influenza Vaccine in London --
more
July 6, 2006
Asterand signs partnership to supply drug discovery services to Japan --
more
July 3, 2006
Solexa Joins Russell 3000 Index --
more
June 30, 2006
Asterand Announces Collaboration with Rubicon Genomics to Develop New Cancer Diagnostic Tests --
more
June 29, 2006
Cyberkinetics Reports Preliminary BrainGate Data from Non-Speaking, Paralyzed Participant at ASIA Meeting in Boston --
more
June 29, 2006
Radius Announces Licensing Agreement to Develop and Commercialize Eisai SERMs --
more
June 23, 2006
European Patent Office Significantly Limits Scope of Kreutzer-Limmer RNAi Patent Claim --
more
June 20, 2006
Rib-X Pharmaceuticals Raises $50 Million in Series C Financing --
more
June 19, 2006
MicroMed Announces Closing of $15.425 Million Financing --
more
June 7, 2006
Ceres and Noble Foundation Establish Collaboration for New Energy Crops --
more
June 5, 2006
Cyberkinetics Reports First Data from Non-Speaking, Paralyzed Participant in Ongoing Study of BrainGate Neural Interface System - Expanded Evidence of Brain Computer Interface Utility Presented at ASSFN Meeting in Boston --
more
June 5, 2006
Xanthus Presents Symadex Phase 1 Results at American Society of Clinical Oncology Meeting --
more
June 5, 2006
Xanthus Meets Milestone in Phase 2 Clinical Study of Xanafide for Treatment of Secondary AML --
more
June 2, 2006
Trubion Files for Initial Public Offering --
more
June 1, 2006
Rib-X Pharmaceuticals and Wakunaga Pharmaceutical Company Announce License Agreement for Quinolone Antibiotic --
more
June 1, 2006
Cyberkinetics and Minnetronix Finalize Design and Manufacturing Agreement for the Andara OFS Device to Treat Acute Spinal Cord Injuries --
more
May 31, 2006
UMass Medical School Partners with PowderMed to Test Potential Avian Flu Vaccine --
more
May 31, 2006
Study in the Journal "Vaccine" Reports Positive Results of DNA-Based Flu Vaccine in Humans --
more
May 24, 2006
Sirna Therapeutics Announces Pricing of Common Stock Offering --
more
May 22, 2006
Xanthus Pharmaceuticals Appoints John Lister-James, Ph.D. as Vice President, Development --
more
May 16, 2006
Solexa Added to NASDAQ Biotech Index --
more
May 10, 2006
Sirna Therapeutics Licenses Worldwide Exclusive Rights to microRNA Technology from University of Massachusetts Medical School --
more
May 4, 2006
Sirna Therapeutics Announces Programs in Strategic Research Alliance With GlaxoSmithKline --
more
May 2, 2006
Critical Therapeutics on Target to Submit NDA for Zileuton Controlled-Release Tablets in Third Quarter 2006 --
more
April 24, 2006
CardioFocus Completes Series C Financing; H.I.G. Ventures and KBL Healthcare Ventures Lead $21.5 Million Round for Developer of First Endoscopically-Guided Catheter Ablation System to Treat Atrial Fibrillation --
more
April 17, 2006
Asterand Announces New Test to Reduce Risks in Human Drug Trials --
more
April 12, 2006
Targacept Announces Pricing of Its Initial Public Offering --
more
April 12, 2006
Radius Appoints Louis O’Dea Senior Vice President and Chief Medical Officer --
more
April 10, 2006
HydroCision receives 2006 ‘Medical Design Excellence Award’ (MDEA) for its SpineJet® MicroResector --
more
April 3, 2006
GlaxoSmithKline and Sirna Therapeutics Announce Major Alliance in RNAi-Based Therapeutics for Respiratory Disease --
more
March 29, 2006
PowderMed's Therapeutic DNA Vaccine for Chronic Hepatitis B Enters Phase 1 Clinical Trials in Patients --
more
March 29, 2006
ExonHit and BioMérieux reach an important research milestone in the molecular detection of breast cancer from blood samples --
more
March 27, 2006
Elixir Pharmaceuticals Acquires Late-Stage Product for the Treatment of Type II Diabetes --
more
March 23, 2006
ACADIA Pharmaceuticals Announces Positive Results From Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease --
more
March 14, 2006
Dynogen Initiates Phase II Trial of DDP225 for Treatment of Chronic Functional Vomiting --
more
March 14, 2006
Sirna Therapeutics Announces Its Scientific Advisory Board --
more
March 10, 2006
X-Cell Begins Trial of its Ethos DES Product Using Estradiol --
more
March 8, 2006
X-Cell Medical Initiates Enrollment for ETHOS II Clinical Trial of Estradiol Eluting Stent --
more
March 1, 2006
R. Scott Greer Named Chairman of the Board of Sirna Therapeutics and Lutz Lingnau Appointed as New Board Member --
more
March 1, 2006
Inverness Medical Innovations Acquires CLONDIAG Chip Technologies --
more
February 28, 2006
Memory Pharmaceuticals Expands Roche Nicotinic Alpha-7 Alliance --
more
February 23, 2006
X-Cell Medical: Putting Safety First --
more
February 21, 2006
Solexa Transfers Listing to The Nasdaq National Market --
more
February 17, 2006
ExonHit Therapeutics Will Begin Continuous Trading on Alternext --
more
February 15, 2006
Critical Therapeutics Completes Dosing of First Patient in Clinical Trial of Intravenous Zileuton --
more
February 9, 2006
ExonHit SpliceArray Service Welcomes Its 50th Commercial Contract --
more
February 6, 2006
Dr. Derek M. Winstanly Joins Xanthus Life Sciences' Board of Directors --
more
January 24, 2006
Astex grants Cytochrome P450 license to Pfizer --
more
January 20, 2006
Solexa Completes Second Closing of $65 Million Private Equity Financing --
more
January 19, 2006
Enanta Pharmaceuticals Announces Initiation of Phase 2 Studies in North America on First-in-Class Antibiotic EDP-420 for the Treatment of Community Acquired Pneumonia --
more
January 17, 2006
Targacept Files for Initial Public Offering --
more
January 17, 2006
Xanthus Initiates Phase 2 Clinical Trial with Symadex in Patients with Metastatic Colorectal Cancer --
more
January 9, 2006
Avalon Pharmaceuticals Initiates AVN944 Phase I Clinical Trial in Cancer Patients --
more
January 5, 2006
AVEO Pharmaceuticals Acquires Rights to Novel Anti-Cancer Compound from Mitsubishi Pharma Corporation --
more
January 3, 2006
Wyeth Announces Strategic Collaboration with Trubion Pharmaceuticals --
more
January 3, 2006
Santhera Announces Management Buy-Out of the Graffinity Drug Discovery Technology Business --
more
January 3, 2006
Xanthus Initiates Phase 2 Clinical Trial with Symadex in Women With Metastatic Breast Cancer --
more
December 28, 2005
Targacept and AstraZeneca Announce Global License and Research Collaboration Agreement --
more
December 22, 2005
Richard W. Dugan Joins Xanthus Life Sciences' Board of Directors --
more
December 22, 2005
Inverness Medical Innovations Receives FDA Clearance for Sale of its Albumin Cobalt Binding (ACB(R)) Test for Detection of Ischemia Modified Albumin (IMA(R)) on Roche Chemistry Analyzers --
more
December 22, 2005
Exelixis and Wyeth Sign License Agreement Related to Novel Treatments for Metabolic and Liver Diseases --
more
December 21, 2005
Sirna Therapeutics Selects Development Candidate for Its Hepatitis C Antiviral Program --
more
December 20, 2005
Critical Therapeutics Initiates Pharmacokinetic Studies of Zileuton Controlled-Release Tablets; Data to support New Drug Application for twice-a-day formulation of zileuton --
more
December 20, 2005
Santhera Raises CHF 25 million (€16 million) Via a Further Closing of its 2005 B Financing Round --
more
December 20, 2005
Enanta Pharmaceuticals Achieves Milestone in Alliance with Shionogi & Co., Ltd. --
more
December 20, 2005
Memory Pharmaceuticals Announces Agreement with the Stanley Medical Research Institute for the Development of MEM 1003 for Bipolar Disorder --
more
December 20, 2005
Memory Pharmaceuticals Announces Preliminary Results from Safety and Tolerability Study for MEM 1003 in Alzheimer's Patients --
more
December 20, 2005
Exelixis Initiates Phase II Clinical Program for XL999 --
more
December 19, 2005
Critical Therapeutics to Initiate Clinical Study of Intravenous Formulation of Zileuton; Phase I/II Asthma Study Scheduled to Begin in the First Quarter of 2006 --
more
December 15, 2005
Santhera Starts European Phase III Study with its Lead Compound SNT-MC17 (idebenone) in Friedrich's Ataxia --
more
December 13, 2005
Radius Announces Licensing Agreement for Ipsen Osteoporosis Proprietary Molecule BA058 --
more
December 12, 2005
Solexa Introduces the Solexa Genome Analysis System --
more
December 8, 2005
Critical Therapeutics Achieves Collaboration Milestone in HMGB1 Program; Demonstrates Efficacy of HMGB1 Antibodies in Preclinical Models of Inflammation --
more
December 6, 2005
Exelixis and Bristol-Myers Squibb Sign New Collaboration Agreement to Develop Novel Cardiovascular Disease Treatments --
more
December 6, 2005
Astex Announces New Licensing and Drug Discovery Alliance to Develop Novel Cell Cycle Cancer Drugs --
more
December 1, 2005
NBC's Today Show Features Cyberkinetics' BrainGate System: In Clinical Trials to 'Turn Thought into Action'; Clinical Trial Participant with Quadriplegia Uses His Own Thoughts to Control a Computer and a Prosthetic Hand --
more
November 24, 2005
New Paper Highlights ExonHit's Novel Approach for the Treatment of Alzheimer's Disease --
more
November 21, 2005
X-Cell Medical Completes Enrollment for Clinical Trial of ETHOS I Estradiol Eluting Stent --
more
November 21, 2005
Solexa Announces Agreement for $65 Million Private Placement --
more
November 21, 2005
Sirna Therapeutics to Join the NASDAQ Biotechnology Index --
more
November 15, 2005
Xanthus Life Sciences Appoints J. Kris Piper as Vice President of Regulatory Affairs and Quality Assurance --
more
November 14, 2005
BioProcessors: Having Identified Rapid, Early Process Development as Critical to the Success of Novo Nordisk’s Biologics Programs, Company Chooses SimCell® MicroBioreactor System For High-Throughput Mammalian Cell Culture Process Development --
more
November 14, 2005
Elixir: Want to Live Forever? --
more
November 8, 2005
FlowMedica Inc., Completes $15 Million Series D Financing --
more
November 7, 2005
Critical Therapeutics' Study Suggests Steroid-Sparing Effect of ZYFLO(R) in Patients with Severe Asthma --
more
November 4, 2005
Memory Pharmaceuticals Commences Phase 2a Trial of MEM 1003 in Alzheimer's Disease --
more
November 3, 2005
Santhera and the NIH Collaborate to Evaluate SNT-MC17 in Friedreich’s Ataxia --
more
November 2, 2005
Critical Therapeutics' ZYFLO(R) Reduces Need for Rescue Medication and Significantly Improves Lung Function in Severe Asthma Patients --
more
November 2, 2005
AVEO Pharmaceuticals and Merck Sign Collaboration for Clinical Drug Response Prediction --
more
October 24, 2005
Cardiome Acquires Artesian Therapeutics --
more
October 20, 2005
Xanthus Initiates a Phase 2 Study Of Xanafide in Combination with ara-C for Treatment Of Secondary AML --
more
October 19, 2005
Santhera Targets New Indication with its Lead Compound --
more
October 18, 2005
BrainCells, Inc. Appoints James A. Schoeneck Chief Executive Officer --
more
October 17, 2005
Memory Pharmaceuticals Announces Collaboration to Develop PDE10 Inhibitors for Central Nervous System Disorders with Amgen --
more
October 17, 2005
Dynogen Initates Phase II Trial of DDP225 for Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome --
more
October 12, 2005
Cellzome and Santhera's business unit, Graffinity, awarded Euro 2.2 million grant from German Government --
more
October 10, 2005
Critical Therapeutics Announces Commercial Launch of ZYFLO(R); Studies Showed ZYFLO Reduced the Need for Rescue Medications and Improved Asthma Symptoms --
more
September 30, 2005
John P. Donoghue Honored for Cyberkinetics' Groundbreaking BrainGate(TM) Brain-Computer Interface at the 'Popular Mechanics 2005 Breakthrough Awards --
more
September 30, 2005
Avalon Pharmaceuticals Announces the Activation of IND for AVN944 for the Treatment of Cancer --
more
September 29, 2005
Avalon Pharmaceuticals Announces Pricing of Initial Public Offering --
more
September 29, 2005
Xanthus Life Sciences Awarded Grant from NCI to Develop Technology for Personalized Dosing of Anticancer Drugs --
more
September 29, 2005
Sirna Therapeutics and Allergan Enter Into Strategic Ophthalmology Alliance --
more
September 28, 2005
Critical Therapeutics Announces FDA Approval of ZYFLO(R) for the Prevention and Chronic Treatment of Asthma; Oral Drug Blocks the Production of Mediators That Can Trigger Asthma Symptoms --
more
September 28, 2005
Dynogen initiates Phase II trial of DDP733 for treatment of patients with constipation-predominant irritable bowel syndrome --
more
September 27, 2005
Cyberkinetics Announces $11.4 Million Private Financing --
more
September 26, 2005
Memory Pharmaceuticals Completes Safety and Tolerability Study of MEM 1003; Preparing to Commence Dosing Patients in Phase 2a Trial --
more
September 23, 2005
Xanthus Life Sciences Appoints John A. McCarthy, Jr. as Senior Vice President and Chief Financial Officer --
more
September 21, 2005
Memory Pharmaceuticals Announces $31 Million Financing --
more
September 19, 2005
Merger of Pharmagene Plc and Asterand, Inc. to Form a Leading Company in Human Tissue Supply and Human Tissue Based Research Services --
more
September 13, 2005
Avalon Pharmaceuticals Announces Small Molecule Drug Discovery Program --
more
September 13, 2005
ACADIA Pharmaceuticals Announces Election of Michael T. Borer to Board of Directors --
more
September 7, 2005
Avalon Pharmaceuticals, Inc. Announces Filing of IND for AVN944 for the Treatment of Cancer --
more
September 6, 2005
Solexa and Collaborating Scientists Illuminate the Small RNA Component of the Transcriptome; Research Published in ''Science'' Demonstrates the Value of High-Throughput Sequencing in Small RNA Analysis --
more
August 31, 2005
Astex announces new drug discovery collaboration with Boehringer Ingelheim --
more
August 29, 2005
Cardiome Announces LOI to Acquire Artesian Therapeutics --
more
August 24, 2005
Dennis H. Langer Appointed to Sirna Therapeutics Board of Directors --
more
August 22, 2005
ALS Patients Offered Access to Cyberkinetics' BrainGate(TM) System in New Pilot Study at Massachusetts General Hospital --
more
August 22, 2005
World Renowned Geneticist David Bentley, D.Phil., Joins Solexa as Chief Scientist --
more
August 17, 2005
X-Cell Medical Commences Randomized Clinical Trial of Estradiol Eluting Stent --
more
August 17, 2005
Biovitrum and Santhera sign an exclusive license and collaboration agreement for the development of DPP-IV inhibitors for the treatment of type 2 diabetes and other metabolic diseases --
more
August 3, 2005
Santhera and Takeda Establish Collaboration to Develop and Market Idebenone (SNT-MC17) in Neuromuscular Disease --
more
August 1, 2005
PowderMed Manufactures a Vaccine Against HSN1 (Avian Influenza) for Clinical Development --
more
July 27, 2005
AstraZeneca and Astex announce new anti-cancer drug discovery alliance --
more
July 26, 2005
BioSource Signs Definitive Merger Agreement and Reports Record Second Quarter Sales --
more
July 25, 2005
Exelixis Initiates Phase I Clinical Trial for Anticancer Compound XL820 --
more
July 25, 2005
First Demonstration of Systemic siRNA Efficacy at Therapeutically Relevant Doses is Published by Sirna Therapeutics --
more
July 14, 2005
BrainCells Inc. Announces $17.7 Million Series A Financing --
more
July 12, 2005
BioProcessors’ SimCell™ Platform Demonstrates Potential to Increase Amgen’s Cell Culture Experiment Capacity --
more
July 12, 2005
Solexa Completes $24 Million Private Equity Financing --
more
July 7, 2005
Sirna Therapeutics Completes Initial Closing of a $28 Million Financing --
more
July 5, 2005
Elixir Pharmaceuticals: Nature Publication Reports Key Links Between Mechanisms of Aging and Metabolic Disorders --
more
July 5, 2005
James B. Tananbaum, M.D. Joins Critical Therapeutics' Board of Directors --
more
June 28, 2005
Cambrios Names Xina Quan as First Vice President of Research & Development --
more
June 27, 2005
US Tissue Bank, Asterand, Expands Service to Europe --
more
June 27, 2005
Astex Announces IND Approval for Novel Cancer Drug AT7519 --
more
June 22, 2005
ACADIA Pharmaceuticals Announces Encouraging Interim Results From Ongoing Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease --
more
June 21, 2005
Critical Therapeutics Announces Closing of $54.5 Million Private Placement --
more
June 20, 2005
MedImmune And Avalon Pharmaceuticals Announce Collaboration to Discover Small Molecule Therapeutic Drugs for Inflammatory Diseases --
more
June 14, 2005
Exelixis Files IND Application for Anticancer Compound XL184 --
more
June 13, 2005
Sirna Therapeutics Announces Collaboration with Massachusetts General Hospital to Evaluate Potential of siRNAs in Hearing Restoration --
more
June 13, 2005
Exelixis Announces Transaction to Fund Clinical Development for XL647, XL999 and XL784 --
more
|